IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial — 4dNanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.

Sam Okafor The fact that it works with lower re-irradiation doses could mean fewer side effects for patients facing this again.

Companies Plan Presentations at H.C. Wainwright ConferenceBusiness — Sep 8, 2026Multiple biotech and mining firms announced participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York this fall, with senior executives set to present or engage in investor meetings to raise visibility. Included are Assembly Biosciences, Nanobiotix, Artelo Biosciences, Fortress Biotech, and U.S. Gold Corp, each outlining presentations or project highlights and strategic discussions.